Pericardial effusion is the accumulation of >50 mL of fluid in the pericardial space, ranging from an incidental asymptomatic finding to life-threatening cardiac tamponade. [1] The hemodynamic impact depends primarily on the rapidity of fluid accumulation rather than absolute volume. [1-2] Approximately half of cases are idiopathic; in North America/Western Europe, postviral infection is the most common identifiable cause, while tuberculosis predominates in endemic regions. [1][3]
The following figure illustrates a comprehensive algorithm for the diagnostic and therapeutic approach to pericardial effusion:
1. History
- Chest pain: Sharp, pleuritic, positional (worse supine, improved leaning forward); present in ~90% of pericarditis-associated effusions [2]
- Dyspnea: Most common presenting symptom overall (65.9% of all pericardial effusions); assess for orthopnea [4-5]
- Timing and onset: Acute vs. subacute vs. chronic (>3 months); rapidity of symptom progression is critical [1][6]
- Triggers: Recent viral illness, cardiac surgery/procedure, chest trauma, radiation therapy, new medications, recent MI [2]
- Associated symptoms: Cough, fatigue, low-grade fever, palpitations, peripheral edema, weight loss (malignancy), night sweats (TB) [2][5]
- Important negatives: Absence of fever, no recent procedures, no immunosuppression, no known malignancy, no TB risk factors — these help stratify risk and guide workup [2]
2. Alarm Features
- Beck's triad: Hypotension, jugular venous distension, muffled heart sounds — classic for tamponade but does not appear commonly in practice [7-8]
- Tachycardia (most sensitive sign of tamponade) and pulsus paradoxus (most specific sign) [7]
- Hemodynamic instability: Hypotension, altered mental status, signs of shock
- Rapid symptom progression: Dyspnea worsening over hours suggests acute accumulation [1]
- High fever (>38°C): Raises concern for purulent pericarditis or systemic infection [1-2]
- Subacute onset without clear trigger: Concerning for malignancy or TB [2]
- Failure to respond to NSAIDs within 1 week [2]
- Large effusion (>2.0 cm) on echocardiography with any symptoms [2]
3. Medications
Drug-induced pericardial effusion/pericarditis: [3][9-10]
- Antineoplastic agents: cyclophosphamide, doxorubicin, daunorubicin, cytarabine, fluorouracil, dasatinib, imatinib
- Lupus-like syndrome: procainamide, hydralazine, isoniazid, methyldopa, phenytoin
- Others: clozapine, mesalamine, minoxidil, immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab), certain vaccines [11]
- Anticoagulants (warfarin, heparin) can cause hemopericardium [12]
Treatment medications: [1-2]
- First-line: Ibuprofen 1600–2400 mg/day or aspirin 650–1000 mg TID + colchicine 0.5 mg BID (3 months acute, ≥6 months recurrent)
- Gastroprotection with PPI recommended with high-dose NSAIDs
- Corticosteroids (prednisone 0.25–0.5 mg/kg/day) only after NSAID/colchicine failure — higher doses increase recurrence risk [2][13]
- Anti–IL-1 agents (anakinra, rilonacept) for refractory inflammatory pericarditis [1]
Contraindications/cautions: [1-2][14]
- NSAIDs: Relative contraindication in heart failure, CKD, peptic ulcer disease, bleeding diathesis, pregnancy >20 weeks
- Colchicine: Contraindicated in severe renal impairment; dose-reduce with P-gp/CYP3A4 inhibitors
- Post-MI pericarditis: Avoid NSAIDs other than aspirin and avoid corticosteroids (risk of impaired myocardial healing) [14]
- Tamponade: Avoid vasodilators, IV diuretics (can precipitate hemodynamic collapse); avoid positive-pressure ventilation and IV sedation if possible [8][15]
4. Diet
- No specific dietary triggers for pericardial effusion
- Hydration: Maintain adequate volume status; dehydration can precipitate tamponade in patients with existing effusions [15]
- Sodium restriction if effusion is secondary to heart failure
- Alcohol avoidance recommended during active anti-inflammatory therapy (GI risk with NSAIDs)
5. Review of Systems
- Cardiovascular: Chest pain, dyspnea, orthopnea, palpitations, syncope/presyncope, peripheral edema
- Respiratory: Cough, pleurisy (concurrent pleural effusion common) [1]
- Constitutional: Fever, fatigue, weight loss, night sweats (TB, malignancy)
- Musculoskeletal/Rheumatologic: Joint pain, rash, oral ulcers (SLE, RA, vasculitis) [3]
- GI: Nausea, anorexia (uremia, malignancy)
- Neurologic: Altered mentation (late tamponade, uremia)
6. Collateral History and Family History
- Collateral: Recent hospitalizations, cardiac procedures, radiation therapy, chemotherapy regimen, dialysis schedule
- Family history: Familial Mediterranean fever, TRAPS (autoinflammatory syndromes), autoimmune diseases (SLE, RA) [3][16]
- Social context: Immigration from TB-endemic areas, incarceration history, homelessness, HIV risk factors, IV drug use [2]
7. Risk Factors
- Infectious: TB-endemic exposure, HIV, immunosuppression [2]
- Malignancy: Lung cancer (~40%), breast cancer (~25%), hematologic malignancies (~20%) — most common causes of malignant effusion [2][17]
- Autoimmune: SLE (up to 20%), RA (30–50% asymptomatic effusions), scleroderma, vasculitis [2]
- Metabolic: Uremia/CKD (25% in some series), hypothyroidism (myxedema) [3-4]
- Iatrogenic: Post-cardiac surgery (20–30%), post-catheter ablation (~10%), radiation therapy (6–30%) [2][17]
- Medications: See section 3 above
8. Differential Diagnosis
- Cardiac tamponade (cannot-miss): Rapid accumulation → hemodynamic compromise [1-2]
- Acute MI / Dressler syndrome: Post-MI pericarditis, typically days to weeks after infarction [14]
- Aortic dissection with hemopericardium: Sudden onset, tearing chest pain, pulse deficits — requires emergent surgical management [8][15]
- Myocarditis / myopericarditis: Troponin elevation, LV dysfunction; ~15% of pericarditis cases [1]
- Pleural effusion: Can mimic on echocardiography — distinguished by position relative to descending aorta on parasternal long-axis view [1][7]
- Epicardial fat pad: Heterogeneous echodensity, moves with myocardium — common echocardiographic mimicker [1-2]
- Constrictive pericarditis: Chronic thickening/calcification, heart failure symptoms without effusion [1]
- Effusive-constrictive pericarditis: Persistent elevated RA pressure after pericardiocentesis [1-2]
9. Past Medical History
- Prior pericarditis episodes (recurrence rate 15–30% after first episode, up to 50% after first recurrence) [1]
- Known malignancy (especially lung, breast, lymphoma)
- Autoimmune disease (SLE, RA, scleroderma)
- CKD/ESRD and dialysis status
- Recent cardiac surgery, catheterization, or ablation
- Radiation therapy history
- HIV status
- Hypothyroidism
10. Physical Exam
Vital signs: [5][7][15]
- Tachycardia: Most sensitive sign of hemodynamic compromise
- Hypotension: Late finding; may be absent early due to compensatory mechanisms
- Pulsus paradoxus: >10 mmHg inspiratory drop in systolic BP — most specific clinical sign of tamponade
Focused exam
- Cardiac: Muffled/distant heart sounds; pericardial friction rub (high-pitched, triphasic, best heard leaning forward — present in <30%, usually absent with large effusions) [2][7]
- JVP: Elevated with tamponade; Kussmaul sign suggests constrictive physiology
- Lungs: Clear (orthopnea without rales distinguishes tamponade from CHF) [15]
- Extremities: Peripheral edema, cool extremities (low output)
- General: Assess for signs of underlying etiology (lymphadenopathy, cachexia, rash, joint swelling)
11. Lab Studies
Recommended initial labs: [1-2]
- CRP/ESR: Elevated in ~78% of inflammatory pericarditis; guides treatment response and recurrence monitoring
- CBC with differential: Neutrophilic leukocytosis suggests inflammatory phenotype; elevated neutrophil-to-lymphocyte ratio [2]
- Troponin: Evaluate for myopericarditis; elevated in ~15% but not a negative prognostic marker if LV function preserved [2]
- BMP/renal function: Rule out uremia
- TSH: Rule out hypothyroidism/myxedema
- Blood cultures: If febrile or concern for bacterial etiology
Directed labs based on clinical suspicion: [2]
- TB testing (QuantiFERON/PPD) if risk factors present
- ANA only if clinical features suggest systemic autoimmune disease (low-level titers are nonspecific)
- HIV serology if risk factors present
Pericardial fluid analysis (if pericardiocentesis performed): [2]
- Cell count, Gram stain, cultures, cytology
- ADA level >40 U/L specific for TB pericarditis [4]
- Triglycerides if chylous effusion suspected
- Do NOT apply Light criteria — normal pericardial fluid is classified as exudative [2]
- Cytology has low sensitivity for malignancy (~75%); 25% of malignant effusions have benign cytology [2]
12. Imaging
First-line: Transthoracic echocardiography (TTE): [1-2]
- Identifies effusion, assesses size and location, evaluates hemodynamic impact
- Effusion sizing (2025 ACC): Trivial (<1.0 cm, not seen throughout cycle), Small (<1.0 cm), Moderate (1.0–1.9 cm), Large (2.0–2.5 cm), Very large (>2.5 cm) [1]
- Tamponade findings: RV diastolic collapse (most specific), RA inversion >1/3 cardiac cycle, IVC plethora (>2.1 cm, no respiratory variation — high sensitivity), respiratory inflow variation (transmitral >30%, transtricuspid >60%) [1]
- POCUS acceptable if formal echo unavailable — look for diastolic RV collapse [2]
Chest X-ray: [2]
- Enlarged cardiac silhouette ("water-bottle heart") only with effusions >300 mL
- Evaluate for pulmonary pathology, pleural effusions, mediastinal masses
Second-line imaging: [1]
- CT chest: Characterizes fluid (transudative <10 HU, exudative 10–60 HU, hemorrhagic >60 HU); evaluates for malignancy, TB, pericardial calcification
- Cardiac MRI (CMR): Assesses pericardial inflammation (LGE, T2 edema), distinguishes active vs. chronic disease; recommended for recurrent/complicated cases
- CCT/CMR not recommended for routine tamponade assessment [1]
13. Special Tests
Diagnostic scoring/risk stratification: [1-2]
- Major risk factors for poor prognosis: High fever, subacute course, large effusion (>2 cm), tamponade, failure to respond to NSAIDs, myopericarditis
- Minor risk factors: Immunosuppression, oral anticoagulant use, recent trauma
Point-of-care tests
- Bedside echocardiography/POCUS: Essential in the ED for rapid identification of effusion and tamponade physiology [2][8]
- Pulsus paradoxus measurement: >10 mmHg systolic drop with inspiration
Procedures: [1-2]
- Pericardiocentesis: Therapeutic for tamponade; diagnostic when bacterial, TB, or malignant etiology suspected
- Approaches: Subxiphoid or apical preferred in emergencies; echo-guided preferred
- Agitated saline injection confirms catheter position [8]
- Drain slowly to avoid pericardial decompression syndrome [8]
14. ECG
ECG findings in pericardial effusion: [7][18-19]
- Low voltage QRS: <0.5 mV in limb leads, <1.0 mV in precordial leads — specific but not sensitive; more associated with tamponade than effusion per se [18][20]
- Electrical alternans: Beat-to-beat variation in QRS amplitude ≥0.1 mV due to swinging heart motion — very specific for tamponade (specificity 98%) but low sensitivity (23%) [18][21]
- Sinus tachycardia: Most common ECG finding; compensatory mechanism [21]
- Diffuse ST elevation and PR depression: Suggests associated pericarditis (present in 25–50%) [2]
The combination of all three (low voltage + electrical alternans + sinus tachycardia) has 100% specificity and 100% PPV for tamponade, though sensitivity is only 8%. [21]
The following figure demonstrates classic electrical alternans with a massive pericardial effusion:
Dangerous patterns to recognize
- Pulseless electrical activity (PEA): Terminal event in tamponade — ECG shows complexes without blood flow [23]
- New atrial fibrillation/flutter: Occurs in ~4% of acute pericarditis [2]
15. Assessment
Severity stratification: [1-2]
- Mild/incidental: Small effusion, asymptomatic, no hemodynamic compromise — often found incidentally
- Moderate: Symptomatic (dyspnea, chest pain) without hemodynamic compromise
- Severe/tamponade: Hemodynamic instability, clinical signs of tamponade
Key clinical pearls
- Hemodynamic impact depends on rate of accumulation, not volume — a rapidly accumulating 200 mL effusion can cause tamponade, while a slowly developing 2 L effusion may be tolerated [1-2]
- ~50% of pericardial effusions are idiopathic [1][3]
- Many patients are asymptomatic — effusion may be an incidental finding [3]
- Complications: Tamponade (<3% of pericarditis cases), constrictive pericarditis (<0.5%), effusive-constrictive pericarditis [2]
16. Treatment Plan
Initial stabilization (tamponade): [8][15][23]
- Emergent pericardiocentesis for hemodynamic instability, impending deterioration, or cardiac arrest
- Gentle IV fluid bolus for hypotensive/hypovolemic patients
- Avoid positive-pressure ventilation and sedation if possible (reduce preload → worsen tamponade)
- Blood products for traumatic hemopericardium
- Dobutamine may be considered for inotropic support, though endogenous stimulation is often already maximal [23]
- Emergent surgery for: Type A aortic dissection, ventricular free wall rupture, severe trauma, uncontrolled iatrogenic bleeding [8]
Inflammatory effusion without tamponade: [1-2]
- Anti-inflammatory therapy should be pursued prior to pericardiocentesis [1]
- Ibuprofen 600–800 mg TID or aspirin 650–1000 mg TID, tapered after symptom resolution and CRP normalization
- Colchicine 0.5 mg BID (0.5 mg daily if ≤70 kg) for 3 months (acute) or ≥6 months (recurrent)
- PPI for gastroprotection
- Exercise restriction ≥1 month (max HR <100 bpm) [1]
Effusion without inflammation: [3][6]
- Treat underlying cause (dialysis for uremia, thyroid replacement for myxedema, chemotherapy adjustment for malignancy)
- Serial TTE surveillance for small-to-moderate effusions
- Exercise restriction not necessary in absence of pericardial inflammation [3]
Pericardiocentesis indications: [1-2]
- Cardiac tamponade (therapeutic) — recommended
- Suspected bacterial, TB, or malignant etiology (diagnostic)
- Pericardiocentesis for effusion without tamponade is not recommended [1]
- If drain placed, leave 3–5 days; consider surgical pericardial window if high output persists at 6–7 days [17]
17. Disposition
Admission criteria: [1-2]
- Large pericardial effusion (>2.0 cm)
- Cardiac tamponade or hemodynamic compromise
- High fever (>38°C)
- Subacute onset without clear trigger (concern for malignancy/TB)
- Failure to respond to prior NSAID therapy
- Suspected bacterial or malignant etiology
- Concomitant myopericarditis with LV dysfunction
- Need for pericardiocentesis
Discharge criteria
- Small-to-moderate effusion without hemodynamic compromise
- Known etiology with appropriate outpatient treatment plan
- Hemodynamically stable, pain controlled on oral anti-inflammatories
- Reliable follow-up arranged (cardiology, repeat echo)
Observation indications
- Moderate effusion with borderline hemodynamics
- New effusion of unclear etiology pending workup results
Specialist consultation triggers: [1][8]
- Cardiology: All moderate-to-large effusions, tamponade, recurrent effusions, need for pericardiocentesis
- Cardiothoracic surgery: Hemopericardium from aortic dissection/trauma, recurrent tamponade requiring pericardial window, loculated effusions not amenable to percutaneous drainage
- Oncology: Suspected or confirmed malignant effusion
- Rheumatology: Suspected autoimmune etiology
- Infectious disease: Suspected TB or purulent pericarditis
18. Follow Up / Return Precautions
Follow-up timing: [1][3][6]
- Repeat TTE within 1 week for moderate-to-large effusions
- Serial TTE surveillance reasonable for at least moderate effusions until stable or resolved [1]
- CRP monitoring to guide anti-inflammatory therapy duration and detect recurrence
- Chronic large asymptomatic effusions: Recent evidence supports watchful waiting as safe, though risk of tamponade progression exists (up to one-third of large effusions) [24-25]
Return precautions — instruct patients to seek immediate care for:
- Worsening shortness of breath or new orthopnea
- Lightheadedness, dizziness, or near-syncope
- New or worsening chest pain
- Rapid heart rate or palpitations
- Swelling in legs or abdomen
- Fever or chills
Patient counseling: [1]
- Activity restriction: Avoid strenuous exercise for ≥1 month if pericardial inflammation present (keep max HR <100 bpm)
- Medication adherence: Complete full course of colchicine — early discontinuation increases recurrence risk
- Recurrence rates: 15–30% after first episode; higher after first recurrence [1]
- Expected recovery: Most idiopathic/viral cases resolve within 4 weeks with appropriate therapy; recurrent cases may require months of treatment [1-2]
References
1. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis: A Report of the American College of Cardiology Solution Set Oversight Committee. — Wang TKM, Klein AL, Cremer PC, et al. Journal of the American College of Cardiology. 2025.
2. Diagnosis, Risk Stratification, and Treatment of Pericarditis: A Review. — Cremer PC, Klein AL, Imazio M. The Journal of the American Medical Association. 2024.
3. Pericardial Diseases: International Position Statement on New Concepts And Advances in Multimodality Cardiac Imaging. — Klein AL, Wang TKM, Cremer PC, et al. JACC. Cardiovascular Imaging. 2024.
4. Pericardial Effusion in an Indian Context: Clinical Insights and Dynamics From a Tertiary Care Centre. — Shaik NJ, Hegde SS, Seshadri S, Cherukuri M. BMC Cardiovascular Disorders. 2024.
5. Recommendations of the Brazilian Society of Surgical Oncology for the Treatment of Neoplastic Pericardial Effusion. — Carvalho EA, Oliveira RENDN, Ribeiro JHA, et al. Journal of Surgical Oncology. 2025.
6. Chronic Pericardial Effusion: Causes and Management. — Lazaros G, Imazio M, Tsioufis P, et al. The Canadian Journal of Cardiology. 2023.
7. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. — Chiabrando JG, Bonaventura A, Vecchié A, et al. Journal of the American College of Cardiology. 2020.
8. Pericardial Tamponade: A Comprehensive Emergency Medicine and Echocardiography Review. — Alerhand S, Adrian RJ, Long B, Avila J. The American Journal of Emergency Medicine. 2022.
9. Acute Pericarditis: Rapid Evidence Review. — Peterson TA, Turner SP, Dolezal KA. American Family Physician. 2024.
10. Drug-Induced Pericarditis: A Systematic Review of All Published Cases. — Collini V, Vignut LS, Venturelli F, Imazio M. International Journal of Cardiology. 2025.
11. Top 10 Drugs Most Frequently Associated With Adverse Events of Myocarditis and Pericarditis. — Cho J, Jo H, Park J, et al. Scientific Reports. 2025.
12. Clinical predictors and outcomes of patients with pericardial effusion in chronic kidney disease. — Ravi V, Iskander F, Saini A, Brecklin C, Doukky R. Clinical Cardiology. 2018.
13. Complicated Pericarditis: Understanding Risk Factors and Pathophysiology To Inform Imaging and Treatment. — Cremer PC, Kumar A, Kontzias A, et al. Journal of the American College of Cardiology. 2016.
14. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Rao SV, O'Donoghue ML, Ruel M, et al. Journal of the American College of Cardiology. 2025.
15. Cardiac Tamponade. — Adler Y, Ristić AD, Imazio M, et al. Nature Reviews. Disease Primers. 2023.
16. The Evolving Etiologic and Epidemiologic Portrait of Pericardial Disease. — Reddy P, Kane GC, Oh JK, Luis SA. The Canadian Journal of Cardiology. 2023.
17. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. — Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Journal of the American College of Cardiology. 2017.
18. The Diagnosis of Pericardial Effusion and Cardiac Tamponade by 12-Lead ECG. A Technology Assessment. — Eisenberg MJ, de Romeral LM, Heidenreich PA, Schiller NB, Evans GT. Chest. 1996.
19. Electrocardiographic Changes in Pericardial Effusion. — Meyers DG, Bagin RG, Levene JF. Chest. 1993.
20. Changes in QRS Voltage in Cardiac Tamponade and Pericardial Effusion: Reversibility After Pericardiocentesis and After Anti-Inflammatory Drug Treatment. — Bruch C, Schmermund A, Dagres N, et al. Journal of the American College of Cardiology. 2001.
21. Role of a 12‐Lead Electrocardiogram in the Diagnosis of Cardiac Tamponade as Diagnosed by Transthoracic Echocardiography in Patients With Malignant Pericardial Effusion. — Argula RG, Negi SI, Banchs J, Yusuf SW. Clinical Cardiology. 2015.
22. Electrical Alternans. — Longo MJ, Jaffe CC. The New England Journal of Medicine. 1999.
23. Acute Cardiac Tamponade. — Spodick DH. The New England Journal of Medicine. 2003.
24. Asymptomatic Chronic Large Pericardial Effusions: To Drain or to Observe?. — Lazarou E, Vlachopoulos C, Antonopoulos A, et al. Journal of Clinical Medicine. 2024.
25. Management of Pericardial Effusion. — Imazio M, Adler Y. European Heart Journal. 2013.